POLY-I-C ACCELERATES DEVELOPMENT OF DIABETES-MELLITUS IN DIABETES-PRONE BB RAT

被引:75
作者
EWEL, CH
SOBEL, DO
ZELIGS, BJ
BELLANTI, JA
机构
[1] GEORGETOWN UNIV,SCH MED,INT CTR INTERDISCIPLINARY STUDIES IMMUNOL,WASHINGTON,DC 20057
[2] GEORGETOWN UNIV,SCH MED,DEPT PEDIAT,WASHINGTON,DC 20057
[3] GEORGETOWN UNIV,SCH MED,DEPT MICROBIOL,WASHINGTON,DC 20057
关键词
D O I
10.2337/diabetes.41.8.1016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We developed a new experimental model of accelerated diabetes mellitus in the genetically susceptible diabetes-prone BB rat with the administration of the IFN-alpha inducer poly I:C. With this model, there was both an increased incidence and accelerated onset of insulin-dependent-diabetes in poly I:C-treated animals compared with saline-treated controls. All twelve rats administered poly I:C (5-mu-g/gm body weight 3 times/wk) developed diabetes by 57 days of age (100%) compared with 1 of 27 (3.7%) saline-treated controls. Furthermore, the development of diabetes was accelerated in the poly I:C-treated group (mean age +/- SE at onset 52.8 +/- 0.58 days) compared with saline-treated controls (89.3 +/- 2.4 days, P < 0.01). Additionally, poly I:C-treated rats had higher mean serum IFN-alpha levels than saline-treated rats at weeks 2 and 3 of treatment (210 vs. 27 and 183 vs. 25 U/ml, respectively, P < 0.001). Poly I:C treatment of 5 Wistar rats, the parental strain, which is not susceptible to diabetes, did not result in insulitis, diabetes, or hyperglycemia. The histopathologic findings of insulitis and decreased immunoreactive islet insulin in poly I:C-accelerated diabetic BB rats and in BB rats with spontaneous diabetes suggest a similar pathophysiology.
引用
收藏
页码:1016 / 1021
页数:6
相关论文
共 24 条
  • [1] ADAM C, 1980, CLIN EXP IMMUNOL, V40, P382
  • [2] DIFFERENTIAL ABILITY OF HUMAN-BLOOD MONOCYTE SUBSETS TO RELEASE VARIOUS CYTOKINES
    AKIYAMA, Y
    STEVENSON, GW
    SCHLICK, E
    MATSUSHIMA, K
    MILLER, PJ
    STEVENSON, HC
    [J]. JOURNAL OF LEUKOCYTE BIOLOGY, 1985, 37 (05) : 519 - 530
  • [3] Armstrong J A, 1981, Methods Enzymol, V78, P381
  • [4] BHAN AK, 1988, DIAGNOSTIC IMMUNOPAT, P437
  • [5] BOTTAZZO GF, 1985, DIABETES ANN, V1, P16
  • [6] THYROID AUTOIMMUNITY IN PATIENTS ON LONG-TERM THERAPY WITH LEUKOCYTE-DERIVED INTERFERON
    BURMAN, P
    TOTTERMAN, TH
    OBERG, K
    KARLSSON, FA
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1986, 63 (05) : 1086 - 1090
  • [7] CARPENTER DF, 1970, LAB INVEST, V23, P628
  • [8] DECLERCQ E, 1987, METHOD ENZYMOL, V78, P227
  • [9] FOULIS AK, 1987, LANCET, V2, P1423
  • [10] ROLE OF ENDOGENOUS INTERFERON IN ANTI-TUMOR EFFECT OF POLY I.C AND STATOLON AS DEMONSTRATED BY USE OF ANTI-MOUSE INTERFERON SERUM
    GRESSER, I
    MAURY, C
    BANDU, MT
    TOVEY, M
    MAUNOURY, MT
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1978, 21 (01) : 72 - 77